Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma

被引：30

作者：

Bygrave, Ceri ^{[1
]}

Pawlyn, Charlotte ^{[2
,3
]}

Davies, Faith ^{[4
]}

Craig, Zoe ^{[5
]}

Cairns, David ^{[5
]}

Hockaday, Anna ^{[5
]}

Jenner, Matthew ^{[6
,7
]}

Cook, Gordon ^{[5
,8
]}

Drayson, Mark ^{[9
]}

Owen, Roger ^{[10
]}

Gregory, Walter ^{[5
]}

Morgan, Gareth ^{[4
]}

Jackson, Graham ^{[11
]}

Kaiser, Martin ^{[2
,3
]}

机构：

[1] Univ Hosp Wales, Heath Pk, Cardiff CF14 4XN, Wales

[2] Inst Canc Res, Sutton, Surrey, England

[3] Royal Marsden Hosp, London, England

[4] NYU, NYU Langone Hlth, New York, NY USA

[5] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England

[6] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[7] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England

[8] St James Univ Hosp, Leeds Inst Med Res, Leeds, W Yorkshire, England

[9] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England

[10] St James Univ Hosp, Haematol Malignancy Diagnost Serv HMDS, Leeds, W Yorkshire, England

[11] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷 / 03期

关键词：

myeloma; transplantation; prognostic factors;

D O I：

10.1111/bjh.16793

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. Relapse within 12 months of autologous stem cell transplant was associated with markedly worse median progression-free survival 2 (PFS2) of 18 months and overall survival (OS) of 26 months, compared to median PFS2 of 85 months and OS of 91 months for later relapsing patients despite equal access to and use of subsequent therapies, highlighting the urgent need for improved outcome prediction and early intervention strategies for myeloma patients.

引用

页码：551 / 555

页数：5

共 9 条

[1] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Hulin, Cyrille ;

Leleu, Xavier ;

Caillot, Denis ;

Escoffre, Martine ;

Arnulf, Bertrand ;

Macro, Margaret ;

Belhadj, Karim ;

Garderet, Laurent ;

Roussel, Murielle ;

Payen, Catherine ;

Mathiot, Claire ;

Fermand, Jean P. ;

Meuleman, Nathalie ;

Rollet, Sandrine ;

Maglio, Michelle E. ;

Zeytoonjian, Andrea A. ;

Weller, Edie A. ;

Munshi, Nikhil ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Facon, Thierry ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc ;

Moreau, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320

[2] Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial [J].

Jackson, Graham H. ;

Davies, Faith E. ;

Pawlyn, Charlotte ;

Cairns, David A. ;

Striha, Alina ;

Collett, Corinne ;

Waterhouse, Anna ;

Jones, John R. ;

Kishore, Bhuvan ;

Garg, Mamta ;

Williams, Cathy D. ;

Karunanithi, Kamaraj ;

Lindsay, Jindriska ;

Wilson, Jamie N. ;

Jenner, Matthew W. ;

Cook, Gordon ;

Kaiser, Martin F. ;

Drayson, Mark T. ;

Owen, Roger G. ;

Russell, Nigel H. ;

Gregory, Walter M. ;

Morgan, Gareth J. .

LANCET HAEMATOLOGY, 2019, 6 (12) :E616-E629

[3] Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial [J].

Jackson, Graham H. ;

Davies, Faith E. ;

Pawlyn, Charlotte ;

Cairns, David A. ;

Striha, Alina ;

Collett, Corinne ;

Hockaday, Anna ;

Jones, John R. ;

Kishore, Bhuvan ;

Garg, Mamta ;

Williams, Cathy D. ;

Karunanithi, Kamaraj ;

Lindsay, Jindriska ;

Jenner, Matthew W. ;

Cook, Gordon ;

Russell, Nigel H. ;

Kaiser, Martin F. ;

Drayson, Mark T. ;

Owen, Roger G. ;

Gregory, Walter M. ;

Morgan, Gareth J. .

LANCET ONCOLOGY, 2019, 20 (01) :57-73

[4] Whole-Body Imaging in Multiple Myeloma [J].

Messiou, Christina ;

Kaiser, Martin .

MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2018, 26 (04) :509-+

[5] New criteria for response assessment: role of minimal residual disease in multiple myeloma [J].

Paiva, Bruno ;

van Dongen, Jacques J. M. ;

Orfao, Alberto .

BLOOD, 2015, 125 (20) :3059-3068

[6] The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma [J].

Rasche, Leo ;

Angtuaco, Edgardo J. ;

Alpe, Terri L. ;

Gershner, Grant H. ;

McDonald, James E. ;

Samant, Rohan S. ;

Kumar, Manoj ;

Van Hemert, Rudy ;

Epstein, Joshua ;

Deshpande, Shayu ;

Tytarenko, Ruslana ;

Yaccoby, Shmuel ;

Hillengass, Jens ;

Thanendrarajan, Sharmilan ;

Schinke, Carolina ;

van Rhee, Frits ;

Zangari, Maurizio ;

Walker, Brian A. ;

Barlogie, Bart ;

Morgan, Gareth J. ;

Davies, Faith E. ;

Weinhold, Niels .

BLOOD, 2018, 132 (01) :59-66

[7] Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients [J].

Shah, V. ;

Sherborne, A. L. ;

Walker, B. A. ;

Johnson, D. C. ;

Boyle, E. M. ;

Ellis, S. ;

Begum, D. B. ;

Proszek, P. Z. ;

Jones, J. R. ;

Pawlyn, C. ;

Savola, S. ;

Jenner, M. W. ;

Drayson, M. T. ;

Owen, R. G. ;

Houlston, R. S. ;

Cairns, D. A. ;

Gregory, W. M. ;

Cook, G. ;

Davies, F. E. ;

Jackson, G. H. ;

Morgan, G. J. ;

Kaiser, M. F. .

LEUKEMIA, 2018, 32 (01) :102-110

[8] Subclonal TP53 copy number is associated with prognosis in multiple myeloma [J].

Shah, Vallari ;

Johnson, David C. ;

Sherborne, Amy L. ;

Ellis, Sidra ;

Aldridge, Frances M. ;

Howard-Reeves, Julie ;

Begum, Farzana ;

Price, Amy ;

Kendall, Jack ;

Chiecchio, Laura ;

Savola, Suvi ;

Jenner, Matthew W. ;

Drayson, Mark T. ;

Owen, Roger G. ;

Gregory, Walter M. ;

Morgan, Gareth J. ;

Davies, Faith E. ;

Houlston, Richard S. ;

Cook, Gordon ;

Cairns, David A. ;

Jackson, Graham ;

Kaiser, Martin F. .

BLOOD, 2018, 132 (23) :2465-2469

[9] High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma [J].

Thakurta, Anjan ;

Ortiz, Maria ;

Blecua, Pedro ;

Towfic, Fadi ;

Corre, Jill ;

Serbina, Natalya V. ;

Flynt, Erin ;

Yu, Zhinuan ;

Yang, Zhihong ;

Palumbo, Antonio ;

Dimopoulos, Meletios A. ;

Gutierrez, Norma C. ;

Goldschmidt, Hartmut ;

Sonneveld, Pieter ;

Avet-Loiseau, Herve .

BLOOD, 2019, 133 (11) :1217-1221

← 1 →